| Demographics |
| Male, n (%) |
703 (53.9) |
392 (55.5) |
311 (52.0) |
0.22 |
2 |
Demographics |
| Female, n (%) |
601 (46.1) |
314 (44.5) |
287 (48.0) |
0.22 |
3 |
Demographics |
| Median Age (IQR) |
63.0 [48.0, 73.0] |
63.0 [47.0, 72.0] |
63.9 [50.0, 73.0] |
0.17 |
4 |
Demographics |
| White, n (%) |
994 (76.2) |
528 (74.8) |
466 (77.9) |
<0.01 |
6 |
Demographics |
| Black, n (%) |
105 (8.1) |
46 (6.5) |
59 (9.9) |
<0.01 |
7 |
Demographics |
| Other/Multiple, n (%) |
129 (9.9) |
80 (11.3) |
49 (8.2) |
<0.01 |
8 |
Demographics |
| Unknown, n (%) |
76 (5.8) |
52 (7.4) |
24 (4.0) |
<0.01 |
9 |
Demographics |
| Not Reported Dead, n (%) |
915 (70.2) |
529 (74.9) |
386 (64.5) |
<0.01 |
11 |
Demographics |
| Reported Dead, n (%) |
389 (29.8) |
177 (25.1) |
212 (35.5) |
<0.01 |
12 |
Demographics |
| Other Insurance, n (%) |
933 (71.5) |
495 (70.1) |
438 (73.2) |
0.24 |
14 |
Demographics |
| Medicaid/Safety Net, n (%) |
371 (28.5) |
211 (29.9) |
160 (26.8) |
0.24 |
15 |
Demographics |
| Hospital Site |
| Mass General Hospital, n (%) |
706 (54.1) |
706 (100.0) |
0 (0.0) |
<0.01 |
17 |
Hospital Site |
| Brigham and Women's Hospital, n (%) |
598 (45.9) |
0 (0.0) |
598 (100.0) |
<0.01 |
18 |
Hospital Site |
| Admitting Service Specialty |
| Neurology, n (%) |
584 (44.8) |
350 (49.6) |
234 (39.1) |
<0.01 |
20 |
Admitting Service Specialty |
| Non-Neurology, n (%) |
720 (55.2) |
356 (50.4) |
364 (60.9) |
<0.01 |
21 |
Admitting Service Specialty |
| Immune Status |
| Immunocompetent, n (%) |
1133 (86.9) |
655 (92.8) |
478 (79.9) |
<0.01 |
23 |
Immune Status |
| Immunosuppressed, n (%) |
171 (13.1) |
51 (7.2) |
120 (20.1) |
<0.01 |
24 |
Immune Status |
| No Transplant, n (%) |
1160 (89.0) |
669 (94.8) |
491 (82.1) |
<0.01 |
26 |
Immune Status |
| History of Transplant, n (%) |
144 (11.0) |
37 (5.2) |
107 (17.9) |
<0.01 |
27 |
Immune Status |
| No B-cell Depleting Meds, n (%) |
1271 (97.5) |
692 (98.0) |
579 (96.8) |
0.23 |
29 |
Immune Status |
| B-cell Depletion, n (%) |
33 (2.5) |
14 (2.0) |
19 (3.2) |
0.23 |
30 |
Immune Status |
| CSF Testing by Month and Hospital Day |
| Test Sent Off-Season, n (%) |
479 (36.7) |
266 (37.7) |
213 (35.6) |
0.48 |
32 |
CSF Testing by Month and Hospital Day |
| Test Sent June-Nov, n (%) |
825 (63.3) |
440 (62.3) |
385 (64.4) |
0.48 |
33 |
CSF Testing by Month and Hospital Day |
| CSF Lab Values |
| CSF Admission Day (IQR) |
1.0 [1.0, 4.0] |
1.0 [1.0, 4.0] |
1.0 [0.0, 4.0] |
0.72 |
34 |
CSF Lab Values |
| CSF Protein (IQR) |
47.5 [31.7, 78.0] |
48.0 [32.0, 81.0] |
46.8 [31.2, 72.1] |
0.23 |
35 |
CSF Lab Values |
| CSF Total Protein < 60, n (%) |
834 (64.0) |
442 (62.6) |
392 (65.7) |
0.28 |
37 |
CSF Lab Values |
| CSF Total Protein ≥ 60, n (%) |
469 (36.0) |
264 (37.4) |
205 (34.3) |
0.28 |
38 |
CSF Lab Values |
| CSF Glucose (IQR) |
68.0 [58.0, 85.0] |
68.0 [59.0, 86.0] |
68.0 [57.0, 84.0] |
0.13 |
39 |
CSF Lab Values |
| CSF Total Nucleated Cell Count (IQR) |
3.0 [1.0, 21.0] |
3.0 [1.0, 29.0] |
2.0 [1.0, 13.8] |
0.18 |
40 |
CSF Lab Values |
| CSF Total Nucleated Cell Count < 5, n (%) |
769 (59.0) |
395 (55.9) |
374 (62.5) |
0.02 |
42 |
CSF Lab Values |
| CSF Total Nucleated Cell Count ≥ 5, n (%) |
535 (41.0) |
311 (44.1) |
224 (37.5) |
0.02 |
43 |
CSF Lab Values |
| CSF Lymphocyte Count (IQR) |
66.0 [25.0, 86.0] |
68.0 [17.0, 88.0] |
62.0 [28.2, 84.8] |
0.77 |
44 |
CSF Lab Values |
| Normal CSF Cell Count (CSF TNC < 5), n (%) |
769 (59.0) |
395 (55.9) |
374 (62.5) |
<0.01 |
46 |
CSF Lab Values |
| Pleocytosis (Lymph ≥ 50%), n (%) |
350 (26.8) |
221 (31.3) |
129 (21.6) |
<0.01 |
47 |
CSF Lab Values |
| Pleocytosis (Lymph < 50%), n (%) |
185 (14.2) |
90 (12.7) |
95 (15.9) |
<0.01 |
48 |
CSF Lab Values |
| Serum Studies |
| Serum WBC (IQR) |
8.2 [5.7, 11.4] |
8.6 [6.0, 11.6] |
7.6 [5.2, 10.9] |
<0.01 |
49 |
Serum Studies |